|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Candel Therapeutics (NASDAQ: CADL) through any online brokerage.
There are no as such competitors for Candel Therapeutics.
The latest price target for Candel Therapeutics (NASDAQ: CADL) was reported by UBS on August 23, 2021. The analyst firm set a price target for 9.00 expecting CADL to fall to within 12 months (a possible -12.88% downside). 3 analyst firms have reported ratings in the last year.
The stock price for Candel Therapeutics (NASDAQ: CADL) is $10.33 last updated Mon Oct 25 2021 20:00:02 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Candel Therapeutics.
Candel Therapeutics’s $Q3 earnings are confirmed for after-market on $December 8, 2021.
There is no upcoming split for Candel Therapeutics.
Candel Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.